Therapeutic applications of fatty acid amide hydrolase inhibitors

US8293724B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• George Kunos · Bethesda, US
• Alexandros Makriyannis · Boston, US

Key dates

• Filing date: Apr 6, 2010
• Grant date: Oct 23, 2012
• Expiry date: Oct 31, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.